

POMBILITI
(cipaglucosidase alfa-atga)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Late-onset Pompe disease (acid alpha-glucosidase (GAA) deficiency)

AND ALL of the following:

- a. Patient has not improved on enzyme replacement therapy (ERT)
- b. Patient weight ≥ 40 kg
- c. Used in combination with Opfolda
- d. Prescriber agrees to monitor for hypersensitivity reactions and infusion-associated reactions and to initiate treatment as needed
- e. Prescriber agrees to frequently monitor the vitals of patients at risk for fluid volume overload during medication infusion
- f. Prescriber agrees to assess for cardiac issues such as cardiomyopathy, cardiac hypertrophy and arrhythmia using an echocardiogram and a 12 lead EKG prior to initiating therapy with Pombiliti
- g. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 60 days after the last dose

Prior - Approval Limits

Duration 2 years

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Late-onset Pompe disease (acid alpha-glucosidase (GAA) deficiency)



**BlueCross
BlueShield**

Federal Employee Program.

**POMBILITI
(cipaglucosidase alfa-atga)**

AND ALL of the following:

- a. Patient weight ≥ 40 kg
- b. Used in combination with Opfolda
- c. Prescriber agrees to monitor for hypersensitivity reactions and infusion-associated reactions and to initiate treatment as needed
- d. Prescriber agrees to frequently monitor the vitals of patients at risk for fluid volume overload during medication infusion
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment and for 60 days after the last dose

Prior - Approval *Renewal* Limits

Same as above